Neurocrine Biosciences, Inc. provided earnings guidance for the full year of 2024. For the year, company expects Net Product Sales of $2,100 million to $2,200 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
131.8 USD | -1.39% | -3.40% | +0.19% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.19% | 13.45B | |
+18.35% | 125B | |
+14.21% | 109B | |
-2.20% | 24.74B | |
+2.71% | 22.67B | |
-9.95% | 18.14B | |
-41.48% | 16.67B | |
-12.48% | 16.64B | |
+23.33% | 11.32B | |
+86.09% | 9.32B |
- Stock Market
- Equities
- NBIX Stock
- News Neurocrine Biosciences, Inc.
- Neurocrine Biosciences, Inc. Provides Earnings Guidance for the Full Year of 2024